GSK (GSK) announced that the US CDC’s Advisory Committee on Immunization Practices has voted to recommend use of Penmvevy as part of the ...

The recommendation will be reviewed and if adopted would allow for vaccination in fewer doses, which may simplify delivery and improve immunization rates, GSK added. In February, the Food and Drug ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya. The shot protects ...

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...

As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and ...

April 3 (Reuters) - British pharmaceutical giant GlaxoSmithKline (GSK.L), opens new tab and rival Pfizer (PFE.N), opens new tab have agreed to end a lawsuit that alleged Pfizer's respiratory ...